

Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision¹

Actives substances(s): Satralizumab

Latest Decision number(s): EMA/PE/0000228512

Corresponding PIP number(s): EMEA-001625-PIP04-22

If the PIP has been submitted as part of a marketing authorisation application in order to comply with the requirements of Article 7 of the Paediatric Regulation (as a condition of the validation of the respective application) and a marketing authorisation was granted based on this application, then there is a legal obligation to complete that PIP. The same applies if there has been a successful post-authorisation application, where the PIP was included in order to comply with the requirements of Article 8 of the Paediatric Regulation.

Please confirm if any of the above applies:

Yes ☐ No ☒

If yes, it means that based on the Marketing Authorisation obtained at the end of that initial procedure or the successful post-authorisation application, as applicable, you are obliged to complete that PIP. That obligation cannot be cancelled by a unilateral decision, including by withdrawing the MA. Such PIP must be completed, unless it is modified in agreement with the PDCO by removing all outstanding PIP measures or granting a full product-specific waiver instead (upon relevant circumstances in accordance with the Paediatric Regulation). Non-completion of a binding PIP establishes noncompliance with the requirements of the Paediatric Regulation, which the European Medicines Agency has an obligation to report to the European Commission.

Please note that development of the medicinal product above in the following **condition(s)/indication(s)**:

Treatment of Autoimmune Encephalitis

☒ has been discontinued

for the following reason(s): (tick all that apply)

☐ (possible) lack of efficacy in adults

☐ (possible) lack of efficacy in children

☐ (possible) unsatisfactory safety profile in adults

☐ (possible) unsatisfactory safety profile in children

☐ commercial reasons (please specify:)

☐ manufacturing / quality problems

☐ other regulatory action (please specify:)

☒ other reason (please specify: Recruitment difficulties)

Please add a brief description (max 2000 characters) of the reason(s) for the discontinuation:

Following a comprehensive internal review of the **WN43174 CIELO study** (Study 3 in the agreed PIP), the Sponsor has identified significant and insurmountable recruitment challenges. Given the rarity

¹ This form will be published to the corresponding decision available on the website of the European Medicines Agency.

of NMDAR-specific Autoimmune Encephalitis, identifying and enrolling a sufficient paediatric population has proven operationally and scientifically unfeasible within a reasonable timeframe. Therefore, the Sponsor has made the decision not to pursue this indication in the European Union. Recruitment will now conclude at approximately 70 patients. While recruitment is stopping earlier than originally planned, the study is not being stopped. All patients enrolled will continue to participate in the study exactly as outlined in the protocol. For the Committee's awareness, please note that no adolescent participants in the EU have been recruited into the study to date.

Name and signature of the PIP contact point:

Date: 14 May 2026

Contact for inquiries from interested parties: Roche Registration GmbH

Telephone: +497624142892

Email: global.eu_regulatory_office@roche.com